Recent News

• 08.13.2025 - BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
• 07.07.2025 - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
• 06.03.2025 - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
• 05.28.2025 - BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
• 05.12.2025 - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 08.13.2025 - 8-K Current report
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.13.2025 - POS AM Post-Effective amendments for registration statement
• 08.13.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 3 Initial statement of beneficial ownership of securities
• 08.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - DEF 14A Other definitive proxy statements
• 08.06.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 07.03.2025 - 8-K Current report
• 05.12.2025 - EX-99.1 EX-99.1